Author

Allan Olson 1

1 Gossamer Bio, Inc.,San Diego,United States

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF THE MAINTENANCE PERIOD OF THE TOUCHSTONE STUDY

William Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert R. D'Haens, Severine Vermeire, Stephen B Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda, Sheila Gujrathi, Allan Olson

ASSESSMENT OF COMPOSITE ENDPOINTS COMPRISING SYMPTOMATIC, HISTOLOGIC, ENDOSCOPIC, AND MOLECULAR IMPROVEMENT IN A PHASE 1B STUDY OF GB004, A GUT-TARGETED, HYPOXIA-INDUCIBLE FACTOR (HIF)-1Α STABILIZER, IN MILD-TO-MODERATE ULCERATIVE COLITIS

Kartik Raghupathi, Robin Osterhout, Brian Feagan, William J. Sandborn, Courtney Van Biene, Allan Olson, Richard Aranda, Barrett G. Levesque, Silvio Danese

EFFICACY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS: ANALYSIS OF THE STEROID-REFRACTORY SUBGROUP FROM THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Gregory J. Opiteck, Allan Olson, Richard Aranda, Marc E. Rothenberg, Ikuo Hirano

ENDOSCOPIC AND CLINICAL EFFICACY DEMONSTRATED WITH ORAL OZANIMOD IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Brian G. Feagan, William Sandborn, Geert R. D'Haens, Barrett G. Levesque, Brett E. Skolnick, Caiyan Li, Darryl Penenberg, Richard Aranda, Allan Olson

LONG-TERM EFFICACY AND SAFETY OF RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY, IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE OPEN-LABEL EXTENSION OF THE HEROES STUDY

Evan S Dellon, Margaret H. Collins, Yehudith Assouline Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Alex Straumann, Ekaterina Safroneeva, Amy Woo, Allan Olson, Gregory J. Opiteck, Richard Aranda, Ikuo Hirano

MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION ARE SIGNIFICANTLY REDUCED IN ACTIVE EOSINOPHILIC ESOPHAGITIS FOLLOWING 16 WEEKS OF TREATMENT WITH RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY

Peter Gann, Ryan Deaton, Nathan McMahon, Margaret H. Collins, Evan S Dellon, Ikuo Hirano, Michael Grimm, Amy Woo, Mahinda Karunaratne, Allan Olson, Richard Aranda, Gregory J. Opiteck

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH OZANIMOD, AN ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: TOUCHSTONE EXTENSION 2-YEAR FOLLOW-UP

William Sandborn, Brian G. Feagan, Geert R. D'Haens, Steve Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Caiyan Li, Darryl Penenberg, AnnKatrin Petersen, Richard Aranda, Allan Olson

SAFETY AND EFFICACY OF LONG-TERM TREATMENT WITH OZANIMOD, AND ORAL S1P RECEPTOR MODULATOR, IN MODERATE TO SEVERE ULCERATIVE COLITIS: TOUCHSTONE EXTENSION

William Sandborn, Brian G. Feagan, Geert R. D'Haens, Stephen B Hanauer, Douglas C. Wolf, Severine Vermeire, Subrata Ghosh, Allan Olson, Heather Smith, Matt Cravets, Paul A. Frohna, Richard Aranda

SAFETY, PHARMACOKINETIC, BIOMARKER, HISTOLOGIC, AND RECTAL BLEEDING ACTIVITY FOLLOWING TREATMENT WITH THE GUT-TARGETED, PHD-INHIBITOR AND HIF-1α STABILIZER GB004 IN A PHASE 1B TRIAL IN MILD-TO-MODERATE ULCERATIVE COLITIS

William Sandborn, Brian G. Feagan, Silvio Danese, Alina Jucov, B.R. Bhandari, Kartik Raghupathi, Allan Olson, Courtney Van Biene, Gregory J. Opiteck, Julia Ford, Richard Aranda, Barrett G. Levesque

Item 1 - 9 / 9
1